RUNX1突变通过破坏抗肿瘤细胞防御促进低危MDS进展:一项低危MDS患者研究
该研究分析214例低危骨髓增生异常综合征(LR-MDS)患者的突变图谱,137例(64%)检出至少一种突变,RUNX1突变被识别为快速进展的主要分子预测因子;RUNX1突变患者CD34+细胞表达谱显示DNA损伤应答和细胞衰老防御受损,且类似高危MDS,提示纳入分子数据可改善LR-MDS风险分层。
要点
- 214例LR-MDS中137例(64%)检出至少一种突变,RUNX1突变为快速进展的主要分子预测因子。
- RUNX1未突变LR-MDS细胞以DNA损伤应答和细胞衰老作为抗肿瘤细胞屏障。
- RUNX1突变LR-MDS表达谱类似初诊高危MDS,提示防御受抑与恶性转化相关。
核心结论
- 纳入分子数据可改善LR-MDS风险分层,RUNX1突变与抗LR-MDS进展防御受抑相关。
研究设计与样本
- 分析214例LR-MDS患者的突变图谱,其中137例(64%)检出至少一种突变。
- 通过统计学和机器学习识别快速进展的主要分子预测因子。
- 比较伴与不伴RUNX1突变的LR-MDS患者CD34+细胞表达谱。
- 通过检测γH2AX表达和β-半乳糖苷酶活性在功能水平观察DNA损伤应答和细胞衰老。
主要发现
- 214例LR-MDS患者中137例(64%)检出至少一种突变。
- RUNX1突变被识别为快速进展的主要分子预测因子。
- RUNX1未突变LR-MDS细胞表达谱提示DNA损伤应答机制和细胞衰老作为抗肿瘤细胞屏障起保护作用。
- RUNX1突变LR-MDS细胞表达谱提示DNA损伤应答和细胞衰老失调。
- RUNX1突变LR-MDS的表达谱类似初诊高危MDS。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with lower-risk myelodysplastic syndromes (LR-MDS) have a generally favorable prognosis; however, a small proportion of cases progress rapidly. This study aimed to define molecular biomarkers predictive of LR-MDS progression and to uncover cellular pathways contributing to malignant transformation. The mutational landscape was analyzed in 214 LR-MDS patients, and at least one mutation was detected in 137 patients (64%). Mutated RUNX1 was identified as the main molecular predictor of rapid progression by statistics and machine learning. To study the effect of mutated RUNX1 on pathway regulation, the expression profiles of CD34 + cells from LR-MDS patients with RUNX1 mutations were compared to those from patients without RUNX1 mutations. The data suggest that RUNX1-unmutated LR-MDS cells are protected by DNA damage response (DDR) mechanisms and cellular senescence as an antitumor cellular barrier, while RUNX1 mutations may be one of the triggers of malignant transformation. Dysregulated DDR and cellular senescence were also observed at the functional level by detecting γH2AX expression and β-galactosidase activity. Notably, the expression profiles of RUNX1-mutated LR-MDS resembled those of higher-risk MDS at diagnosis. This study demonstrates that incorporating molecular data improves LR-MDS risk stratification and that mutated RUNX1 is associated with a suppressed defense against LR-MDS progression.
引用
- Kaisrlikova M, Vesela J, Kundrat D, et al. RUNX1 mutations contribute to the progression of MDS due to disruption of antitumor cellular defense: a study on patients with lower-risk MDS. Leukemia. 2022. PMID: 35505182. doi:10.1038/s41375-022-01584-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。